Unlike reversible quiescence, cellular senescence is characterized by a large flat cell morphology, β-gal staining and irreversible loss of regenerative (i.e., replicative) potential. Conversion from proliferative arrest to irreversible senescence, a process named geroconversion, is driven in part by growth-promoting pathways such as mammalian target of rapamycin (mTOR). During cell cycle arrest, mTOR converts reversible arrest into senescence. Inhibitors of mTOR can suppress geroconversion, maintaining quiescence instead. It was shown that hypoxia inhibits mTOR. Therefore, we suggest that hypoxia may suppress geroconversion. Here we tested this hypothesis. In HT-p21-9 cells, expression of inducible p21 caused cell cycle arrest without inhibiting mTOR, leading to senescence. Hypoxia did not prevent p21 induction and proliferative arrest, but instead inhibited the mTOR pathway and geroconversion. Exposure to hypoxia during p21 induction prevented senescent morphology and loss of regenerative potential, thus maintaining reversible quiescence so cells could restart proliferation after switching p21 off. Suppression of geroconversion was p53-and HIF-1-independent, as hypoxia also suppressed geroconversion in cells lacking functional p53 and HIF-1α. Also, in normal fibroblasts and retinal cells, hypoxia inhibited the mTOR pathway and suppressed senescence caused by etoposide without affecting DNA damage response, p53/p21 induction and cell cycle arrest. Also hypoxia suppressed geroconversion in cells treated with nutlin-3a, a nongenotoxic inducer of p53, in cell lines susceptible to nutlin-3a-induced senescence (MEL-10, A172, and NKE). Thus, in normal and cancer cell lines, hypoxia suppresses geroconversion caused by diverse stimuli. Physiological and clinical implications of the present findings are discussed.
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oncology | gerontology | biology R ecent evidence emerges that the mammalian target of rapamycin (mTOR) pathway is involved in cellular aging (1, 2) . Nutrients, cytokines, growth factors, and hormones activate the mTOR pathway, which drives cellular mass growth (3, 4) . In proliferating cells, cellular growth in size is balanced by cell division. When the cell cycle is arrested and cells thus do not divide, inappropriate activation of growth-promoting pathways such as mTOR converts cell cycle arrest into senescence (1, 2) . Senescence is characterized by a large flat cell morphology, β-gal staining, and a hypersecretory phenotype (5, 6) . In a widely used cellular model, induction of ectopic p21 by isopropyl-thio-galactosidase (IPTG) arrests HT-p21-9 cells (7, 8) . Initially (during 2-3 d), this condition is reversible: when p21 is switched off, cells resume proliferation (7, 8) . While inhibiting the cell cycle, p21 does not inhibit mTOR, which in turn converts arrest into irreversible senescence (1) . By day 3, cells become large, flat, and β-gal-positive, and lose regenerative potential (RP): cells cannot resume proliferation when p21 is switched off. The conversion from reversible arrest to senescence, a process named geroconversion (9) , is suppressed by rapamycin. Thus, rapamycin preserves RP in arrested cells, so the condition remains reversible: cells can resume proliferation when p21 is switched off. The involvement of mTOR in geroconversion links cellular senescence to organismal aging. Geroconversion is a cell culture model of cellular aging in the organism. In fact, inhibition of the mTOR pathway prolongs lifespan in diverse organisms, including mammals (10-20).
Importantly, agents that inhibit mTOR can suppress geroconversion even though they cause reversible arrest on their own (21) (22) (23) . As an example, while causing cell cycle arrest, p53 may decelerate or suppress geroconversion by inhibiting mTOR (in some conditions and cell lines) (21) (22) (23) . Hypoxia can cause cell cycle arrest. Simultaneously, hypoxia decreases cap-dependent translation, by inhibiting the mTOR pathway, as well as global translation by phosphorylating eukaryotic initiation eIF2a and elongation eEF2 factors (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Given that hypoxia inhibits the mTOR pathway, we suggest that hypoxia should suppress geroconversion during cell cycle arrest caused by other agents, which otherwise cause senescence. Here we tested this hypothesis.
Results
Hypoxia Suppresses p21-Induced Senescence. Initially, we investigated effects of hypoxia on p21-induced senescence in HT-p21-9 cells. In these cells, IPTG induces ectopic p21, which causes cell cycle arrest and senescence (1, 2, 7, 8, (21) (22) (23) . First, we investigated whether hypoxia affects the mTOR pathway. Hypoxia decreased phosphorylation of S6K (substrate of mTOR) and S6 (substrate of S6K; Fig. 1A ). In contrast, like rapamycin, hypoxia did not affect basal p53 and p21 (Fig. 1A) and did not prevent p21 induction by IPTG (Fig. S1A ). As expected, hypoxia did not prevent the proliferative arrest caused by IPTG. In the presence of IPTG, cells did not proliferate under hypoxia and normoxia (Fig. S1 ). In agreement with previous results (1, 2, 7, 8) , IPTG caused a senescent morphology (Fig. 1B) . Hypoxia partially prevented a large flat cell morphology (Fig. 1B) and β-gal staining ( Fig. 1 B and C) . Most importantly, hypoxia prevented loss of RP: the potential of IPTG-arrested cells to resume proliferation ( Fig.  1D and Fig. S1C ). When treated with IPTG under normoxia, cells lost RP and could not resume proliferation when IPTG was removed ( Fig. 1D ). Rapamycin and hypoxia preserved RP during IPTG-induced arrest. Furthermore, when we treated cells with IPTG under different conditions (normoxia, rapamycin, hypoxia, rapamycin plus hypoxia) and, after 3 to 4 d, washed and cultured them under normoxia, IPTG-pretreated cells could not resume proliferation and did not form colonies (Fig. 1E ). Hypoxia and rapamycin prevented loss of RP in IPTG-pretreated cells so that cells formed colonies (Fig. 1E) . To exclude that hypoxia abrogated IPTG-induced arrest in some rare cells, which then could form colonies, we also treated cells with IPTG in the presence of nocodazole, which eliminates cells not arrested by IPTG (37) (Fig. 1E ). Like rapamycin, hypoxia preserved RP in the presence of nocodazole (Fig. 1E ). This indicates that neither rapamycin nor hypoxia prevented IPTG-induced arrest. Furthermore, hypoxia by itself caused cell cycle arrest in HT-p21-9 cells (Fig. S2) . Noteworthy for further discussion, there was no additive effect of rapamycin and hypoxia (Fig. 1E) . Next, we investigated whether the potential of cells to replicate was not limited to eight to 10 divisions, required to form visible colonies during 7 d of culture after removal of IPTG. Starting at day 8 after removal of IPTG, growth curves demonstrated that cells pretreated with IPTG under hypoxia fully recovered, whereas cells cultivated with IPTG under normoxia did not (Fig. 1F) . It is noteworthy that hypoxia did not potentiate the effect of rapamycin (Fig. 1F ).
Suppression of Senescence by Hypoxia Is Not p53-and HIF-1-Dependent.
Induction of p53 can inhibit the mTOR pathway (38) (39) (40) (41) (42) . We have shown that induction of p53 inhibited geroconversion in IPTG-treated HT-p21-9 cells (21, 23) . Therefore, we investigated whether the effect of hypoxia was mediated by p53 induction. However, hypoxia did not induce p53 in these cells ( Fig.   1A and Fig. S1A ). Next, we determined whether the effect of hypoxia requires the p53 function by using parental HT-p21-9 and HT-p21-9-GSE56 cells, which lack functional p53 (21, 43, 44) . As expected, in HT-p21-9-GSE56 cells, IPTG-induced senescence was preventable by rapamycin but not by nutlin-3a (21) (Fig. 2A) . Hypoxia preserved RP in both cell lines ( Fig. 2A ). There was no additive effect of rapamycin and hypoxia ( Fig. 2A) . Next, we investigated whether HIF-1α was required for suppression of senescence by hypoxia by using siRNA technology to knock HIF-1α out. Hypoxia dramatically induced HIF-1α in control cells, whereas siRNA for HIF-1α prevented this induction (Fig. 2B) . Despite lack of HIF-1α induction, hypoxia inhibited S6 phosphorylation (Fig. 2B ). This result is in agreement with previous report that regulation of mTOR by hypoxia does not require HIF1α (26) . Importantly, hypoxia preserved RP regardless of HIF-1α expression (Fig. 2C) .
Hypoxia Suppresses Etoposide-Induced Senescence in Normal Cells.
Next, we investigated the effect of hypoxia on senescence in normal cells. To induce senescence, we used low concentrations of etoposide, which has been shown to cause senescence in normal retinal pigment epithelial (RPE) and human tert-immortalized fibroblast WI-38t cells (23, 45) . Specifically, cells become large, β-gal-positive and lose RP, so they could not resume proliferation when etoposide was removed. Rapamycin partially preserved RP without affecting DNA damage or cell cycle arrest (45) . Here we show that, like rapamycin, hypoxia inhibited S6 phosphorylation in RPE cells (Fig. 3A) . Unlike rapamycin, hypoxia increased phosphorylation of eEF2 (Fig. 3A) . Also, hypoxia prevented cell enlargement (Fig. 3B) . Importantly, when treated with etoposide under hypoxia, RPE cells partially retained RP and resumed proliferation after removal of etoposide (Fig. 3C) . Cells that resumed proliferation fully recovered with almost normal exponential growth by day 10 (Fig. S3) . Hypoxia also suppressed senescent morphology, β-gal staining, and partially preserved RP in WI38t cells (Fig. S4) . It is noteworthy that hypoxia did not decrease levels of DNA damage response caused by etoposide in these cells. Specifically, etoposide-induced p53, p21, and p-H2AX were not decreased by hypoxia (Fig. S5) .
Hypoxia Suppresses Nutlin-3a-Induced Senescence. We next investigated senescence caused by nongenotoxic induction of p53 by nutlin-3a. In several cell lines, nutlin-3a causes cell cycle arrest, but, at low concentrations, it does not inhibit mTOR, thereby leading to senescence (21) (22) (23) 37) . In normal kidney epithelial (NKE) cells, nutlin-3a induced p53 and p21 but only slightly affected pS6 (Fig. 4A) . Rapamycin suppressed pS6 without affecting p53 and p21 induction (Fig. 4A) . Hypoxia did not prevent induction of p53/p21 by nutlin-3a and inhibited pS6 especially in nutlin-treated cells. Accordingly, hypoxia prevented senescent morphology (Fig. 4B) and partially preserved RP in nutlintreated NKE cells (Fig. 4C) . We extended these observations to additional cell lines, demonstrating inhibition of senescent morphology by hypoxia in MEL-10, A172, and TRT-HU1 cells (Figs. S6-S7 ), in which senescence was caused by nutlin-3a or etoposide. We further investigated the effect of hypoxia on senescence of stem cells. It is known that bone marrow-derived mesenchymal stem cells (MSCs) proliferate more efficiently in hypoxic conditions (46) . To induce senescence, we treated these cells with nutlin-3a under normoxia or hypoxia. Cells treated under normoxia lost RP, whereas cells treated under hypoxia were able to resume proliferation after removal of nutlin-3a (Fig. S8) .
We noticed that hypoxia increased p-eEF2 in NKE cells (Fig.  4A ) and other cells (Fig. 3A) . However, results obtained in MEL-9 and MEL-10 cells did not support the role of p-eEF2 in the gerosuppressive effect by hypoxia. These two related cell lines responded slightly differently to hypoxia. Although HIF-1α and p-eEF2 was induced in both cell lines, only in MEL-10 did we observe inhibition of the mTOR pathway (p-S6K and pS6; Fig.  5A ). In agreement, hypoxia preserved RP only in MEL-10 cells (Fig. 5B) . Hypoxia also decreased senescent morphology and β-gal staining caused by nutlin-3a in MEL-10 ( Fig. 5C ). Thus, hypoxia inhibits mTOR and geroconversion in one cell line (MEL-10), but causes eEF2 phosphorylation in both MEL cell lines (Fig. 5A) , indicating that this effect is irrelevant to suppression of senescence. As a second argument, rapamycin decreased (rather than increased) p-eEF2 (Fig. 5A ) in MEL-10 and -9 but efficiently suppressed senescence in these cells (Fig.  5C ), consistent with our previous publication (22) . The only similarity in effects of hypoxia and rapamycin on senescence was inhibition of S6K/pS6. We next investigated the involvement of the LKB1/AMPK pathway, which acts upstream of both mTOR and eEF2 (24) . In MEL10 and MEL9 cell lines, hypoxia induced phosphorylation of AMPK, in parallel with phosphorylation of eEF2 (Fig. 5) . However, phosphorylation of AMPK was much stronger in MEL-9 cells compared with MEL-10 cells, even though hypoxia did not suppress geroconversion in MEL-9 cells. Thus, phosphorylation of AMPK/eEF2 was not sufficient for gerosuppressive effects of hypoxia. Moreover, phosphorylation of AMPK and eEF2 was not necessary, given that rapamycin did not cause phosphorylation of AMPK and eEF2 in any cell lines tested. Furthermore, AMPK and eEF2 were paradoxically dephosphorylated by hypoxia in HT-p21-9 cells (Fig. S9 A and B) . These results are in agreement with previous reports that regulation of mTOR by hypoxia does not correlate with AMPK phosphorylation (26) and does not require AMPK or LKB1 (27) . Finally, we did not detect changes in SIRT1 levels under hypoxia (Fig. S9) , with the exception that hypoxia prevented downregulation of SIRT1 in IPTG-treated HT-p21-9 cells (Fig. S9B) . However, rapamycin did not decrease SIRT1 levels (Fig. S9) . Thus, the only consistent changes associated with geroconversion with both rapamycin and hypoxia was inhibition of the S6K/S6 pathway.
Discussion
It is well known that hypoxia induces cell cycle arrest. Cell cycle arrest by itself is not yet senescence. Senescence requires additional components, including activation of growth-promoting and nutrient-sensing pathways such as mTOR (9) . When the cell cycle is arrested, growth-promoting (i.e., anabolic) signaling pathways drive cellular mass growth, as well as compensatory lysosomal hyperactivity with cytoplasmic β-gal staining, hypersecretory phenotype, and permanent loss of proliferative potential (9) . Numerous studies demonstrated that hypoxia inhibits the mTOR pathway by multiple mechanisms, depending on experimental conditions and cell lines (24-36, 47, 48) . We confirmed here that hypoxia deactivated the mTOR pathway in our cellular models of geroconversion. Rapamycin suppressed geroconversion in these cellular models. Like rapamycin, hypoxia prevented irreversible cellular senescence.
It was previously shown that hypoxia prevents replicative senescence in MEFs by preventing cell cycle arrest (49). Here we described suppression of geroconversion by hypoxia (a completely unique phenomenon) rather than prevention of cell cycle arrest. In already arrested cells, hypoxia suppressed the conversion of cell cycle arrest into senescence. We caused cell cycle arrest by both DNA damaging (i.e., etoposide) and nondamaging (i.e., ectopic p21 and nutlin-3a) agents. Hypoxia did not prevent H2AX phosphorylation, p53/p21 induction, and cell cycle arrest caused by DNA damage, but instead inhibited the mTOR pathway. In the arrested cells, hypoxia decreased the mTOR activity and senescent phenotype and preserved RP. Most importantly, hypoxia prevented geroconversion during cell cycle arrest caused by ectopic p21 and nutlin-3a, which did not damage DNA.
There are several implications of the present findings. Physiological cellular aging is a conversion of postmitotic cells into senescent cells. It is noteworthy that levels of oxygen in most normal tissues are lower than 1% to 3%. This suggests that low levels of oxygen can decelerate premature conversion to senescence and extend lifespan. Also, stem cell niches are often extremely hypoxic (50) (51) (52) ; perhaps this preserves a quiescent (not senescent) status of stem cells. Finally, hypoxia may play a dual role in aging (53) . It suppresses mTOR and geroconversion; conversely, hypoxia induces HIF-1, which increases secretion of mitogens and cytokines. The physiological outcome may be determined by all factors.
Materials and Methods
Cell Lines and Reagents. HT-p21-9 cells, derived from HT1080 human fibrosarcoma cells (American Type Culture Collection), provided by Igor Roninson (University of South Carolina, Charleston, SC), were previously described (1, 2, 7, 8) . HT-p21-9-GSE56 cells, which lack transcriptional function of p53, were described previously (21, 43, 44) . HT-p21-9 cells were cultured in highglucose DMEM without pyruvate supplemented with FC2 serum (HyClone FetalClone II; Thermo Scientific). In these cells, p21 expression can be turned on or off by using IPTG (7, 8) . WI38-Tert cells (WI38 fibroblasts immortalized by Tert) were described previously (22, 23) . RPE (2), NKE, MEL9 and MEL10 melanoma cell lines, and A172 glioblastoma cells were obtained from American Type Culture Collection. TRT-HU1 (hTERT-immortalized nontransformed human urothelial cells) was established and provided by Joseph DiDonato (Cleveland Clinic, Cleveland, OH) (54) . Cancer cell lines were cultured in high-glucose DMEM (plus pyruvate) with 10% FBS. RPE cells were maintained in MEM plus 10% (vol/vol) FBS, and WI38-Tert and NKE cells were cultured in low-glucose DMEM plus 10% (vol/vol) FBS. Mouse MSCs were isolated from bone marrow of mice according to the technical protocol from STEMCELL Technologies. MSCs were cultured in complete MesenCult medium (mouse) obtained from STEMCELL Technologies. Rapamycin was obtained from LC Laboratories and dissolved in DMSO as 5 mM solution. IPTG (Invitrogen) was dissolved in water as 50 mg/mL stock solution and used in cell culture at final concentration of 1.25 to 50 μg/mL. Nutlin 3a, etoposide, and nocodazole were from Sigma-Aldrich, and were dissolved in DMSO.
Immunoblot Analysis. Whole cell lysates were prepared by using boiling lysis buffer (1% SDS, 10 mM Tris HCl, pH 7.4). Equal amounts of proteins were separated on gradient Criterion polyacrylamide gels (Bio-Rad) and transferred to PVDF membranes. The following antibodies were used: rabbit anti-phospho-S6 (Ser235/236) and mouse anti-S6, mouse anti-phospho p70S6K, rabbit anti-phospho-eEF2, anti-phospho AMPK and anti-SIRT1 from Cell Signaling; anti-actin antibody from Sigma-Aldrich, and mouse anti-HIF-1a and anti-p21 from BD Biosciences; and mouse anti-p53 (Ab-6) from Oncogene. Secondary anti-rabbit and anti-mouse HRP-conjugated antibodies were from Cell Signaling.
SA-β-Gal Staining. β-Gal staining was performed by using a Senescence β-gal staining kit (Cell Signaling Technology) according to the manufacturer's protocol. Cells were incubated at 37°C until β-gal staining became visible. Development of color was detected under a light microscope.
siRNA Technology. ON-TARGETplus SMART pool siRNA for human HIF-1α was purchased from Thermo Scientific. HT-p21-9 cells were transfected with HIF1a siRNA as described in detail in the legend to Fig. 2. RP Assay. Cells were plated at low density, and treated with senescenceinducing agents (IPTG, etoposide, and nutlin-3a, depending on cell lines) for 3 to 4 d under normoxia or hypoxia, with or without rapamycin. Then, cell numbers were measured (i.e., initial cell numbers) and drugs were washed off. Cells were incubated in fresh drug-free medium under normoxia for 5 to 7 d, and then cell numbers were measured (i.e., final cell numbers). RP was determined as a ratio between final and initial cell numbers as fold increase in cell numbers after drugs were washed off.
Colony Formation Assay. Cells were plated at low density, and treated with senescence-inducing agents (IPTG, etoposide, or nutlin-3a, depending on cell lines) for 3 to 4 d under normoxia or hypoxia, with or without rapamycin. Then, drugs were washed off, and cells were incubated in fresh drug-free medium under normoxia for 7 to 12 d. Plates were fixed and stained with 1.0% crystal violet.
